Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
  • A61K31/717—Celluloses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/74—Synthetic polymeric materials
  • A61K31/785—Polymers containing nitrogen
  • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
  • A61K31/79—Polymers of vinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present invention relates to a composition for a rapidly disintegrable tablet comprising a therapeutically effective amount of amlodipine free base.
• Amlodipine a generic name for the compound of the following formula, 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-l,4- dihydro-3,5-pyridine dicarboxylate, is a long-term calcium-channel blocker useful for treating cadiovacular diseases such as hypertension, coronary occlusion, angiospasm, and anectasis.
• Korean Patent Publication No. 1995-7228 discloses pharmaceutically acceptable amlodipine acid salts, e.g., a hydrochloride, acetate, maleate, salisylate, succinate, mesylate, tosylate and besylate.
• a conventional tablet form of amlodipine besylate is marketed by Pfizer Inc. as NORVASCTM .
• the NORVASCTM tablet is prepared by formulating amlodipine besylate with a conventional excipient such as anhydrous calcium hydrogen phosphate and microcrystalline cellulose.
• oral intake of this tablet is not easy to those having deglutition difficulties or to patients having restricted water-intake.
• compositions for an amlodipine-containing rapidly disintegrable tablet which disintegrates rapidly in the oral cavity without leaving unpleasant water-insoluble residues or generating bitter taste, and exhibits a therapeutically effect comparable to that of a general type amlodipine tablet.
• a composition for a rapidly disintegrable tablet comprising a therapeutically effective amount of amlodipine free base having an average particle size of 2 to 30 ⁇ m.
• Figs. 1 to 4 results for the dissolution test of a rapidly disintegrable tablet prepared according to Example of the present invention and a reference tablet, in pH 1.2, pH 4.0, and pH 6.8 buffer solutions and water, respectively.
• Fig. 5 results for in vivo test of a rapidly disintegrable tablet prepared according to Example 6 of the present invention and a reference tablet.
• the inventive rapidly disintegrable tablet composition is characterized by employing amlodipine in the form of a free base, not a salt, as an active ingredient.
• Amlodipine free base used in the present invention is commonly known to have a lower water-solubility, and further a lower disintegrability and bioavailability, than those of various amlodipine salts (see Korean Patent Publication No. 1995-7228, and D.M. McDaid et al., International Journal of Pharmaceutics 133, 71-83 (1996)).
• the amlodipine besylate has a water-solubility higher than amlodipine free base by a factor of bout 59.4.
• amlodipine free base is not suitable for use in a rapidly disintegrable tablet for oral administration.
• the use of amlodipine salts having a high water-solubility for oral administration has the problem of generating bitter taste in the oral cavity.
• the present inventors have endeavored to improve the disintegrability of amlodipine free base, and the objective has been met by controlling the particle size of the amlodipine free base.
• the amlodipine free base preferably has a particle size ranging from 2 to 30 ⁇ m.
• the amlodipine free base may dissolve in the oral cavity, leaving a bitter taste, whereas if the particle size exceeds 30 ⁇ m, the free base exhibits low disintegrability in the gastric tract.
• the inventive amlodipine-containing rapidly disintegrable tablet composition has such a high disintegration degree that it is easily disintegrated by the action of saliva in the oral cavity to form an emulsion which migrates into the gastric tract without the need to intake water.
• the term "therapeutically effective amount” refers to the amount which produces the desired therapeutic response upon oral administration and can be readily determined by one skilled in the art.
• amlodipine free base may be suitably used in an amount ranging from about 0.1 to 10 % by weight, preferably about 0.5 to 5 % by weight, based on the total weight of the tablet composition.
• the tablet composition of the present invention may further comprise an oral dissolution enhancer, which enhances the dissolution rate in the oral cavity of the tablet.
• the oral dissolution enhancer may be preferably a polyhydric alcohol, representative examples of which include mannitol, sorbitol, lactose, dextrose, xylitol, sucrose, glucose, dextrate, galactose, maltose, maltodextrine, levulose and erythritol.
• the oral dissolution enhancer may be preferably used in a spray-dried form.
• cellulose, microcrystalline cellulose, starch or its derivative may be used as the oral dissolution enhancer.
• the oral dissolution enhancer may be used in an amount ranging from about 10 to 95 % by weight, preferably about 30 to 90 % by weight, based on the total weight of the tablet composition.
• the inventive tablet composition may also contain one or more pharmaceutically acceptable additives.
• a disintegrant may be used to increase the function of the oral dissolution enhancer.
• disintegrant may include a crosslinked polyvinypyrrolidone(crospovidone), carboxymethyl cellulose calcium, crosslinked carboxymethyl cellulose sodium (croscarmellose sodium), hydroxypropyl cellulose, and sodium starch glycolate.
• the disintegrant may be employed in an amount ranging from about 1 to 10 % by weight based on the total weight of the tablet composition.
• compositions may include a cellulose-based excipient for enhancing the moldability under compression of the tablet composition, e.g., a microcrystalline cellulose, starch and cellulose; an organic acid for improving the organoleptic feeling in the oral cavity, e.g., citric acid, tartaric acid and malic acid; a sweetening agent, e.g., aspartame, potassium acesulfam, sodium saccharin, ammonium glycyrrhizinate; a flavor; and a pigment.
• the cellulose compound may be used in an amount ranging from about 1 to 30 % by weight based on the total weight of the tablet composition, and the organic acid, sweetening agent, flavor or pigment may be used in amount ranging from about 0.5 to 5 % by weight based on the total weight of the tablet composition.
• additives may be also used in the present invention, including but not limited to: lubricants such as silicon dioxide, colloidal silicon dioxide, magnesium stearate, talc, magnesium trisilicate, sodium stearyl fumarate, stearic acid and polyethylene glycol; surfactants for increasing the water-solubility and disintegrability of the drug such as non-ionicl sufactant (e.g., polysorbates) and ionic surfactants (e.g., sodium lauryl sulfate); and sucrose esters, each of which may be employed in an amount ranging from about 0.5 to 5 % by weight based on the total weight of the tablet composition.
• lubricants such as silicon dioxide, colloidal silicon dioxide, magnesium stearate, talc, magnesium trisilicate, sodium stearyl fumarate, stearic acid and polyethylene glycol
• surfactants for increasing the water-solubility and disintegrability of the drug such as non-ionicl sufactant (e.g.
• the inventive composition may be formed into a tablet using a conventional manner, e.g., by a direct tableting method, or a granulating and tableting method.
• a conventional manner e.g., by a direct tableting method, or a granulating and tableting method.
• the Examples and Test Examples are given for the purpose of illustration only, and are not intended to limit the scope of the invention.
• the ingredients shown in Table 3 were passed through a 20-mesh sieve (U.S. standard sieve) and mixed for 5 minutes.
• the powder mixture was compressed with a pressure of 90 kgf/cnf by a roll compactor to obtain a granule.
• the resulting granule was passed through a 20-mesh sieve (U.S. standard sieve) and then compressed to obtain a rapidly disintegrable 200mg tablet (Hardness: about 4 ⁇ 5 Kp).
• amlodipine, spray-dried lactose and citric acid were mixed and passed through a 20-mesh sieve (U.S. standard sieve), and the resulting powder mixture was granulated using purified water with a high-speed granulator.
• the granule was dried at 80 °C and passed through a 30mesh sieve (U.S. standard sieve).
• the remaining ingredients excluding magnesium stearate, magnesium trisilicate and stearic acid were passed through a 20-mesh sieve (U.S. standard sieve) and then combined with the granule obtained in the above.
• Example 7 The same procedure as described in Example 1 was repeated except that the ingredients shown in Table 7 were employed to obtain a rapidly disintegrable 150 mg tablet (Hardness: about 4 - 5 Kp).
• Comparative Example 2 The same procedure as described in Example 2 was repeated except that the ingredients shown in Table 8 were employed to obtain a rapidly disintegrable 150 mg tablet (Hardness: about 3 - 4 Kp). Table 8
• Example 3 The same procedure as described in Example 3 was repeated except that the ingredients shown in Table 9 were employed to obtain a rapidly disintegrable 150 mg tablet (Hardness: about 3 - 4 Kp).
• Comparative Example 5 The same procedure as described in Example 5 was repeated except that the ingredients shown in Table 11 were employed to obtain a rapidly disintegrable 300 mg tablet (Hardness: about 6 - 7 Kp).
• Example 6 The same procedure as described in Example 6 was repeated except that the ingredients shown in Table 12 were employed to obtain a rapidly disintegrable 150 mg tablet (Hardness: about 3 - 4 Kp).
• the hardness of each tablet was measured with a tablet hardness tester (Schleuniger-2E, Dr. K. Schleuniger & Co.). The test was repeated 3- 10 times for each sample and the results were averaged.
• the time for a sample to completely disintegrate by the action of saliva in the oral cavity was measured employing six male adults. The test was duplicated three times and the results were averaged.
• the organoleptic test was conducted according to the cross-over method, which is carried out in double blinded at random, employing six male adults.
• Table 13 shows that there are no significant differences in the disintegration time between the tablets of Examples 1 - 6 and those of Comparative Examples 1 - 6, and in case of the tablets of Examples 1 - 6, bitter taste of the active ingredients was effectively masked.
• Test Example 2
• Example 6 Comparative dissolution tests between the tablet prepared in Example 6 (hereinafter “Test tablet”) and a commercially available tablet containing Amlodipine besylate (Norvasc ® 5mg, PFIZER; hereinafter “Reference tablet”) were carried out in water or buffer solutions of pH 1.2, pH 4.0 and pH 6.8, respectively (50rpm, 900ml). The results are shown in Figs. 1 to 4 (Fig. 1 : dissolution in a pH 1.2 buffer solution, Fig. 2: dissolution in a pH 4.0 buffer solution, Fig. 3: dissolution in a pH 6.8 buffer solution, and Fig. 4: dissolution in water). As shown in Figs. 1 to 4, there is no significant difference in dissolution time between two tablets.
• Reference tablet (Norvasc 5mg, PFIZER ) using beagle dogs under fast.
• the test was carried out according to the cross-over method. That is, after cross- administration of Test tablet and Reference tablet to the test dogs, blood samples were taken at present times and the drug concentrations were measured. The concentration profile of amlodipine for each tablet is shown in Fig. 5 which illustrates that Test tablet is biologically equivalent to Reference tablet.

Applications Claiming Priority (2)

Publications (1)

Family

ID=34420543

Family Applications (1)

Country Status (2)

Cited By (7)

Families Citing this family (2)

Citations (5)

• 2003
  • 2003-10-08 KR KR20030069806A patent/KR100604034B1/ko not_active IP Right Cessation
• 2004
  • 2004-10-08 WO PCT/KR2004/002574 patent/WO2005032553A1/en active Application Filing

Patent Citations (5)

Also Published As

Similar Documents

Legal Events